- Home
- / Jeil Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Jeil Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩14.1 K
2024-10-29
Market Capitalization
₩205.5 B
2024-10-29
Revenue
₩704.5 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 627.1B | 671.4B | 691.3B | 700.7B | 722.2B | 726.4B | 704.5B |
| Cost of goods sold | 478.9B | 502.6B | 490.2B | 527.3B | 541.3B | 532.4B | 515.8B |
| Gross profit | 149.1B | 169.6B | 201.7B | 176.4B | 181.4B | 194.5B | 189.1B |
| Gross profit margin, % | 25.3% | 29.2% | 25.2% | 25.1% | 26.8% | 26.8% | |
| Operating expense total | 134.2B | 160.9B | 179.2B | 180.9B | 185.6B | 175.5B | 196.4B |
| Depreciation and amortization | 6.6B | 7.6B | 9.0B | 9.1B | 8.9B | 9.8B | 11.3B |
| EBITDA | 12.9B | 8.5B | 23.2B | (2.7B) | (4.3B) | 19.8B | (6.8B) |
| EBITDA margin, % | 1.3% | 3.4% | -0.4% | -0.6% | 2.7% | -1.0% | |
| EBIT | 6.0B | 43.6M | 13.7B | (11.9B) | (13.8B) | 8.5B | (17.8B) |
| EBIT margin, % | 0.0% | 2.0% | -1.7% | -1.9% | 1.2% | -2.5% | |
| Interest income | 10.7M | 135.8M | 75.3M | 75.8M | 115.6M | 1.0B | 1.2B |
| Interest expense | 1.6B | 1.2B | 1.1B | 2.0B | 3.0B | 6.0B | 5.1B |
| Pre tax profit | 4.9B | (940.9M) | 12.6B | (13.8B) | (13.2B) | 1.9B | (27.0B) |
| Income tax expense | 3.0B | 9.6B | 5.6B | 1.2B | 1.8B | (3.3B) | 3.2B |
| Net Income | 1.9B | (10.6B) | 7.0B | (15.0B) | (15.0B) | 5.2B | (30.1B) |